Tag Archives: NICE

Value-Based Assessment in the UK: The Patient View

By Leela Barham. Patients are influential in the UK when it comes to access to medicines: their individual stories are highlighted in the media and the groups that represent them are credited with major policies. For example, the Rarer Cancer Foundation (RCF) has been credited in large part with the introduction of the Cancer Drugs […]
Posted in Europe, Guest Blog, Op-Ed, pricing | Also tagged , , , , , | Leave a comment

Value-Based Assessment in the UK: The Industry View

By Leela Barham. In the UK, Value-Based Pricing (VBP) has morphed into Value-Based Assessment (VBA), with the National Institute for Health and Care Excellence (NICE) tasked with taking the loose policy concepts (established as far back as 2010) and actually implementing them. Earlier this year, NICE set out its approach, which boiled down to taking a […]
Posted in Europe, Global, Guest Blog, pricing, Regulatory | Also tagged , , , , , | Leave a comment

NICE in Conflict-of-Interest Controversy

They say the road to hell is paved with good intentions. The row in the UK over NICE’s call to doctors to increase the use of statins looked to be good example of this handy aphorism. That was until things took a potentially darker turn.
Posted in Europe, healthcare, pricing | Also tagged , , | Leave a comment

Sanofi Responds to UK’s Value-Based Assessment Plans

By Leela Barham. The UK’s National Institute for Health and Care Excellence (NICE) set out their proposals for value-based assessment (VBA) in March 2014.  VBA is what value-based pricing (VBP) has essentially morphed into. Much work is going on behind closed doors to inform responses as the consultation closing date of the 20th June 2014 […]
Posted in Europe, Global, Guest Blog, healthcare, Op-Ed, pricing, Regulatory | Also tagged , , , , | Leave a comment

UK: Patient Group Sets Out Orphan Drug Charter

By Leela Barham. There has been a lot of concern about the decision to give the National Institute for Health and Care Excellence (NICE) the responsibility to look at “highly specialized technologies” (HSTs, or orphan drugs to you and me). That decision was taken just as the NHS across England was going through major reform […]
Posted in Europe, Global, Guest Blog, healthcare, Op-Ed, Orphan Drugs, Patient Communication, patient education, pricing, Regulatory | Also tagged , , , , , , , | Leave a comment
  • Categories

  • Meta